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Abstract Testing for total antinuclear antibodies (ANA) is
a critical tool for diagnosis and management of autoim-
mune diseases at both the primary care and subspecialty
settings. Repurposing of ANA from a test for lupus to a test
for any autoimmune condition has driven the increase in
ANA requests. Changes in ANA referral patterns include
early or subclinical autoimmune disease detection in
patients with low pre-test probability and use of negative
ANA results to rule out underlying autoimmune disease. A
positive result can lead to further diagnostic considerations.
Currently, ANA tests are performed in centralized labora-
tories; an alternative would be ANA testing at the clinical
point-of-care (POC). By virtue of its near real-time data
collection capability, low cost, and ease of use, we believe
the POC ANA has the potential to enable a new paradigm
shift in autoimmune serology testing.
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Significance of ANA testing
Autoantibodies are essential serological markers that define
and classify most autoimmune diseases. Testing for total
antinuclear antibodies (ANA of undefined specificity and
which includes anti-cytoplasmic autoantibodies) has
become an invaluable tool at both the primary care and
subspecialty settings as a window into further clinical
investigation. The presence of total ANA triggers follow-
up diagnostic studies for specific autoimmune disorders
that are part of the diverse clinical landscape seen in
rheumatology, neurology, oncology, and in infectious,
pulmonary, and renal diseases among others. In many of
these conditions ANA constitutes part of classification and
diagnostic criteria for those diseases. The total and ANA
sub-serology tests also facilitate differential diagnosis and
its refinement [1], predict incipient disease [2], indicate
disease severity or impending flares [3], serve as prognostic
markers for further organ involvement [4], monitor efficacy
of therapy [5], and asses induction of autoimmunity by
drugs [6].
The present article attempts to summarize current trends
in ANA serology testing by diverse physician groups and to
provide ideas on how point-of-care delivery of ANA results
may produce the framework, knowledge, and practices
which may benefit patients, providers, and the health care
industry as a whole. While methods for ANA detection
have markedly evolved in recent years, newer method-
ologies generally require expensive instrumentation and/or
central clinical laboratories. An inexpensive and reliable
point-of-care device for ANA testing could be applicable
not only in communities with modern health care infras-
tructures but also in more resource-poor settings that
struggle with provision of medical care and high burden of
disease.
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Changes in ANA ordering pattern
There are many factors, which determine a physician’s test
ordering practices. These include diagnostic, prognostic,
and therapeutic factors, as well as patient-related factors
(reassurance), doctor-related factors (individual clinical
experience and confidence in clinical judgment; fear of
litigation), and organization-related factors (test availabil-
ity; institutional policies) among others [7]. Regarding
ANA testing, the current increase in ANA requests may
also be a consequence of two additional factors: (1)
repurposing of ANA from a test for lupus to a test for
diverse autoimmune diseases and (2) the expanded and
central role of the primary care physician (PCP) in the
health care delivery system. Today, ANA test ordering
practice follows one of the following patterns:
1. Intent to diagnose (subspecialists)
ANA testing is routinely performed during initial eval-
uation of patients with increased pre-test probability for
autoimmune disease [8], the consequence of which
includes substantial morbidity, mortality, and general
health care costs. Negative ANA can provide a quick way
for ruling out disease, while positive ANA can lead to
further diagnostic consideration and sub-serology testing.
2. Intent to refer (primary care physicians, PCP)
According to the CDC and Prevention’s National Ambu-
latory Medical Care Survey [9], more than half of doctor’s
visits are made to primary care offices in outpatient settings.
A PCP can have long-standing relationships with their
patients, and it is only natural that they are at the center of the
referral decision process. Important triggers for a referral
recommendation by a PCP to a specialist are the clinical
characteristics associated with the patient’s presenting health
problem [10]. In the case of suspected autoimmune disease,
thesemay be systemic but vague and non-specific complaints,
and tests like ANA capture information that are needed to
justify referring the patient to a specialist. Negative ANA can
provide a quick way for ruling out disease.
3. Intent to case find for early disease prevention (PCPs)
In an insightful review and commentary on ANA testing
[11] M. Fritzler points out that the early detection of
autoimmune disease is critical to ensure that treatment is
promptly administered to minimize the development of
disabling conditions. Case finding should be proactive; it
usually works in low pre-test disease probability situations,
and uses symptoms, risk factors, and/or demographics at an
individual level to inform assessment, management, referral,
and education [12]. This approach is promising for diseases
with long preclinical periods (a feature of most autoimmune
disorders). It attempts to achieve pathology prevention by
avoiding factors that trigger disease or using therapy that
modules the destructive process before the onset of clinical
symptoms [13, 14]. The existing literature on the predictive
significance of ANA-associated rheumatic diseases justifies
active case finding in practice as one of the main goals of the
PCP when ordering an ANA test [11].
4. Intent to reassure patient (PCPs and subspecialists)
Testing with the intent of ‘‘reassurance’’ is not infre-
quent, despite the fact that when done for symptoms with
low risk of serious illness, it is doing little to decrease
anxiety or resolve complaints, but may reduce further
primary care visits [15].
Market needs
The total global autoimmune diagnostic tests’ market is
predicted to reach $14.2 billion by 2020 [16]. While market
growth is due in part to the increased use of multiplex
testing in which many analytes from single or multiple
samples undergo high-throughput semi-automated screen-
ing, there remains an underlying need for only single
sample testing for one analyte. For example, there are
many circumstances in which a patient presents to primary
care or emergency medicine physician with nonspecific
symptoms in which the utilization of specific tests such as
ANA is particularly informative [11, 17].
Current clinical needs
Current ANA testing is performed exclusively in central-
ized clinical laboratories. This is a protracted, labor-in-
tensive, and expensive procedure that can slow the
diagnostic process and restricts use in a large segment of
the population. Also, the requirement for blood drawing,
transport to the testing lab, blood processing, test execu-
tion, and communication of results is cumbersome, time
consuming, error prone and costly, which detract from its
diagnostic value. Primary care physicians recognize delays
in test result review as a significant problem affecting
quality of care and patient safety—‘‘I wish I has seen this
test result earlier’’, even raising malpractice concerns [18].
Point-of-care (POC) ANA testing
POC diagnostics is gaining momentum in different areas of
patient care, as its short turnaround time and minimal
manual requirements enable quick clinical management
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decisions [19]. Biosensors based on electrochemical tech-
nology offer promise to streamline diagnostic laboratory
testing, thereby improving productivity by minimizing
costs, time and errors. Electrochemical sensors are partic-
ularly well suited for clinically relevant analytes due to
their high sensitivity and selectivity with minimal back-
ground noise, small size, and power capable by low-volt-
age battery. Electrochemical POC ANA measurement has
potential to meet the expanding testing needs in autoim-
mune serology, while overcoming the limitations of the
‘gold-standard’ indirect immunofluorescence method
(Table 1). In addition to fulfilling the needs in primary care
and in urgent/emergency care clinics, POC testing for ANA
could be useful in remote or rudimentary settings with the
goal of improving diagnostics, enhancing existing test
result follow-up protocols, and facilitating timely medical
intervention for patients [19].
A prototype biosensor for ANA
We have described development and application of an
electrochemical biosensor for rapid quantitation of total
ANA having performance characteristics well correlated
with ANA titer determination by indirect immunofluores-
cence in a clinical laboratory [20]. The immunoreactive
surface consists of a native autoantigen-rich substrate lar-
gely derived from an inexpensive commercially available
source that is bound to a porous membrane at high antigen
density. By forced transport of the test sample through the
membrane loaded with excess autoantigen, antibody–anti-
gen complex formation is complete in less than 3 min.
Detection of isotype-specific autoantibodies is achieved by
transporting a high-affinity secondary antibody conjugated
to peroxidase. Addition of enzyme–substrates results in
production of a redox active intermediate transiently cap-
tured on the electrode, permitting its detection by amper-
ometry under low voltage. The readout on a digital display
is proportional to the amount of antigen-bound antibody.
Of particular importance, the autoantigen substrate is
devoid of DFS-70/LEDGF, a troublesome antibody-bind-
ing ligand of no diagnostic value that detracts from the
utility of ANA testing for autoimmune disease [21]. Unlike
multiplex testing that is restricted to a limited number of
selected autoantigens, the total ANA biosensor employs a
complex mix of potential autoantigens and has the plas-
ticity and capacity to accommodate additional antigenic
species to produce a universal platform for ANA screening.
The ‘‘Choosing Wisely Initiative’’ and a biosensor
for total ANA
In 2012, the American Board of Internal Medicine Foun-
dation (Philadelphia, PA) launched the ‘‘Choosing Wisely’’
campaign, aiming to advance a dialogue on avoiding
wasteful and unnecessary medical tests, treatments, or
procedures. Specialty society partners American College of
Rheumatology [22] and Canadian Rheumatology Associ-
ation [23] contributed recommendations for appropriate
Table 1 Comparison between the standard indirect immunofluorescence method and electrochemical sensor for ANA measurement
Feature Indirect immunofluorescence Electrochemical sensor
Cost
Equipment Costly fluorescence microscope, infrastructure Low cost
Individual test Low–moderate cost Low cost
Access to providers Off-site clinical laboratory Point-of care
Operator expertise Substantial training needed Simple to operate
Readout and interpretation Subjective signal intensity and pattern Objective continuous digital scale output
Assay time Substantial processing time (*3 h) Near real-time data (*20 min)
Result report Semi-quantitative ? pattern Quantitative; no pattern
Methodology logistics
Steps Multiple manipulations Single-step measurement
Sample autonomy Usually run in sample batches Single sample per run
Equipment re-use No restrictions Requires cleaning
Antigen substrate
Antigenic complexity Fairly comprehensive More limited
Potential for improvement None Readily enhanced at additional cost
Clinical false positives due to DFS70 Present Absent
Control for non-specific binding None Blank substrate
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ANA utilization, stressing that duplicative ANA testing is
not warranted if there is high pre-test probability for
immune-mediated disease and/or active disease. In this
situation, sub-serology testing for antigen-specific autoan-
tibodies can enable stratification of patients into particular
autoimmune diseases [22]. However, in situations where
there is minimal or even no suggestion of an immune-
mediated disease other than vague symptoms, screening for
total ANA could be most impactful [11]. Even though the
pre-test probability for an ANA-related disease may be
low, testing for ANA offers the chance to case-find pre- or
early autoimmune disease so that organ damage might be
prevented (see ANA ordering pattern #3). To this end, the
availability to primary care physicians of a convenient
POC ANA testing platform could enhance the goal of
improving patient outcomes and reducing health care costs.
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